You treat the most complex patients in medicine. Your billing should match.
In buy-and-bill medicine your practice pays for the drug before the claim is paid. We take that billing work so clinicians and office staff can spend more time with their patients.
A denied claim is a drug invoice you already paid.
The figures below are industry results, not Brixa results. They show why unfought denials matter in specialty medicine.
of appealed Medicare Advantage prior-authorization denials were overturned
of those denials were appealed
of rheumatology infusion prior authorizations were initially denied
Sources: KFF analysis of CMS data, 2024 determinations (80.7% and 11.5%). Wallace et al., Arthritis Care & Research, 2020 (21%).
What we do
Benefits, eligibility, and prior authorization
We verify coverage and run the prior-authorization process before the drug leaves inventory.
Coding, charge capture, and clean claims
J-code units, NDC, and waste modifiers are checked before a claim goes out.
Denial recovery and appeals
A specialist reviews every appeal. Nothing is sent automatically.
Analytics, margin, and inventory
We reconcile what you bought, administered, and billed, by drug and by payer.
Rheumatology first.
We started with rheumatology because biologics, infusions, and step therapy pull clinicians and office staff off the patients in front of them. These are drugs practices in this specialty often purchase before the claim clears.
Humira Adalimumab
Enbrel Etanercept
Rinvoq Upadacitinib
Orencia Abatacept
Remicade Infliximab
Actemra Tocilizumab
Who we are
Fred Leffler, Andrew Weinburger, and Dan Hakansson, co-founders. We exist so the people who run the practice can spend their day with patients, not with payer portals.
We handle protected health information under HIPAA and sign a Business Associate Agreement with every practice. Security and compliance